The results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone (Tokyo P3R): A multicenter, randomized, phase II, non-placebo-controlled trial

Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 982-988

  Tsujino, Takeshi ^a,b   Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Ito, Yukiko ^b   Togawa, Osamu ^c   Toda, Nobuo ^d   Arizumi, Toshihiko ^e   Kogure, Hirofumi ^f   Yamamoto, Keisuke ^a   Mizuno, Suguru ^a   Yashima, Yoko ^a   Yagioka, Hiroshi ^a   Sasaki, Takashi ^a   Matsubara, Saburo ^a   Yamamoto, Natsuyo ^a   Hirano, Kenji ^a   Sasahira, Naoki ^a   Tada, Minoru ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c JR Tokyo General Hospital   (Japan)

^d TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f Mutual Aid Association of Public School Teachers   (Japan)

Author keywords

Post ERCP pancreatitis; Risperidone; Ulinastatin

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; AMYLASE; RISPERIDONE; TRIACYLGLYCEROL LIPASE; ULINASTATIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHOLANGITIS; CHOLECYSTITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERENZYMEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; PANCREAS DISEASE; PANCREATITIS; PHASE 2 CLINICAL TRIAL; POST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPROTEINS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATITIS; RISPERIDONE; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRYPSIN INHIBITORS; YOUNG ADULT;

EID: 84884353635     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0698-5     Document Type: Article

References (29)

1. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909-18.
2. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425-34.
3. Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002;56:652-6.
4. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139-47.
5. Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol. 2010;105:1753-61.
6. Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. JOP. 2007;8:509-17.
7. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc. 2003;58:23-9.
8. Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc. 2005;62:245-50.
9. Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007;66:1126-32.
10. Sherman S, Alazmi WM, Lehman GA, et al. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointest Endosc. 2009;69:462-72.
11. Sherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009;38:267-74.
12. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med. 1996;335:919-23.
13. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414-22.
14. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:376-83.
15. Oguchi H, Terashima M, Koiwai T, et al. Effects of the S2-serotonergic receptor antagonist, ketanserin, on cerulein-induced pancreatitis in the rat. Life Sci. 1992;50:733-7.
16. Yoshino T, Yamaguchi I. Possible involvement of 5-HT2 receptor activation in aggravation of diet-induced acute pancreatitis in mice. J Pharmacol Exp Ther. 1997;283:1495-502.
17. Ogawa T, Sugidachi A, Tanaka N, et al. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis. Eur J Pharmacol. 2005;521:156-63.
18. Hamada K, Yoshida M, Isayama H, et al. Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice. J Pharmacol Sci. 2007;105:240-50.
19. Yamaguchi I, Hamada K, Yoshida M, et al. Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. J Pharmacol Exp Ther. 2009;328:256-62.
20. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
21. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-21.
22. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383-93.
23. Li Y, Hao Y, Zhu J, et al. Serotonin released from intestinal enterochromaffin cells mediates luminal non-cholecystokinin-stimulated pancreatic secretion in rats. Gastroenterology. 2000;118:1197-207.
24. Zhu JX, Zhu XY, Owyang C, et al. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J Physiol. 2001;530:431-42.
25. Centurión D, Ortiz MI, Sánchez-López A, et al. Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation. Br J Pharmacol. 2001;132:983-90.
26. De Clerck F, Somers Y, Mannaert E, et al. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther. 2004;26:1261-73.
27. Ito T, Ikeda U, Shimpo M, et al. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation. 2000;102:2522-7.
28. Kubera M, Maes M, Kenis G, et al. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005;134:251-8.
29. Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63(Suppl 4):3-11.